Immuron

Immuron Limited is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a new class of specifically targeted polyclonal antibodies, which we believe can address significant unmet medical needs. The company was incorporated under Australian law in 1994 and has been listed on the Australian Securities Exchange (ASX) since April 30, 1999, with our common stock trading under the symbol "IMC." Immuron completed its initial public offering on NASDAQ Capital Market in June 2017, with our American Depositary Shares and warrants listed on NASDAQ under the symbols "IMRN" and "IMRNW," respectively. Each ADS represents 40 shares of our common stock, no par value. Our validated technology platform enables the production of orally active polyclonal antibodies that can be delivered directly to the gastrointestinal ("GI") tract and are largely excluded from the bloodstream. We believe our lead product candidate, currently in clinical development, has the potential to transform existing treatment paradigms for moderate-to-severe campylobacteriosis, Clostridioides difficile infections, enterotoxigenic Escherichia coli (ETEC) infections, and traveler’s diarrhea, a gastrointestinal condition commonly caused by pathogenic bacteria and their toxins.